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Association of schistosomiasis and risk of
prostate cancer development in residents
of Murehwa rural community, Zimbabwe
Emilia T. Choto1* , Takafira Mduluza2,3, Francisca Mutapi4 and Moses J. Chimbari1
Abstract
Background: Prostatic male genital schistosomiasis and prostate cancer co-existence cases are uncommon
however, some studies have indicated that schistosomiasis may trigger development of prostate cancer regardless
of age. Schistosomiasis is a public health problem in sub-Saharan Africa and may account for some undocumented
cases of schistosomiasis prostatic cancer in schistosome endemic rural communities. It is against this background
that we investigated the association between schistosomiasis and risk of prostate cancer development in residents
of Murehwa Community, a schistosomiasis endemic area.
Methodology: We conducted a cross sectional study involving 366 men residing in Murehwa District, Zimbabwe.
Schistosoma haematobium and S. mansoni infection was diagnosed using urine filtration and Kato Katz techniques,
respectively. Haematuria was detected using urinalysis reagent strip test. A structured questionnaire was used to
obtain history of schistosomiasis infection among study participants. Risk of prostate cancer development was
assessed by measuring prostate-specific antigen levels in serum using the ELISA.
Results: Prevalence of S. haematobium and S. mansoni infection was 12.3% and 1.4%, respectively. Individuals with
schistosomiasis had higher prostate-specific antigen levels (mean 1.208 ± SD 1.557 ng/mL) compared to those
without schistosomiasis (mean 0.7721 ± SD 1.173 ng/mL; p < 0.05). Older individuals > 50 years had higher prostate
specific antigen levels (mean 0.7212 ± SD 1.313 ng/mL) compared to individuals < 50 years old (mean 0.4159 ± SD
0.8622 ng/mL; p < 0.05). Prostate-specific antigen levels log10 (mean 0.2584 ± SD 0.2128 ng/mL) and were associated
to S. haematobium infection intensity log10 (mean 1.121 ± SD 0.5371 eggs/10 mL), r(s) = − 0.3225, p < 0.05. There was
a correlation between prostate-specific antigen levels log10 (mean 0.2246 ± SD 0.1858 ng/mL) and S. haematobium
infection intensity log10 (mean 1.169 ± SD 0.5568 eggs/10 mL) among participants with a history of schistosomiasis
infection (r(s) = − 0.3520; p < 0.05). There was no correlation between prostate-specific antigen levels of > 4 ng/mL
(mean 5.324 ± SD1.568 ng/mL) and schistosome eggs log10 (mean 1.057 ± SD 0.6730 eggs/10 mL; p > 0.05).
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Conclusion: Urogenital schistosome infections and history of schistosome infections were associated with prostate
specific antigen levels, an indicator for risk of prostate cancer. Therefore, S. haematobium schistosome egg burden
was associated with the risk of prostate cancer development in adult males residing in Murehwa District,
Zimbabwe.
Keywords: Schistosomiasis, Male genital schistosomiasis, Prostate cancer, Prostate specific antigen, S. haematobium,
S. mansoni, Urogenital schistosomiasis
Introduction
Prostatic male genital schistosomiasis (MGS) and pros-
tate cancer co-existence cases, have been reported since
the 1980s [1] and continue to recur as recently reported
by Lodhia et. al. (2020) [2]. Prostate cancer is a common
urogenital condition living in both schistosomiasis and
non-schistosomiasis endemic areas. Despite geographical
locations, coincidences of MGS infections and prostate
cancer cases have also been reported in non-schistosome
endemic areas [3–5]. The concurrent incidences of pros-
tatic MGS and prostate cancer have prompted the sug-
gestion of a causal association between the two diseases.
Prostate cancer is the second most common cancer
after lung cancer and the fifth leading cause of cancer-
associated mortality among men worldwide [6]. More
than 1 million new cases were recorded in 2018 and the
disease accounts for approximately 4% deaths caused by
cancer in men [7]. In Zimbabwe, prostate cancer is the
most common and leading cause of death [8]. Limited
existing literature on prostate cancer in Zimbabwe
showed that there was major increase in prostate cancer
incidences by 6.4% annually from 1991 to 2010 due to
westernization of lifestyles [9]. In 2017, Zimbabwe Can-
cer Registry reported that prostate cancer accounts for
more than 25% percent of all cancers affecting men
hence a public health problem in the country [10]. More
than 80% of prostate cancer cases are diagnosed very late
and the disease contributes to 9% of cancer related
deaths yearly to cancer [10].
The risk of prostate cancer is associated with men
above 50 years, ethnicity, race, geographic region and
family history of prostate cancer [11, 12]. Prostate cancer
diagnosis is assessed by a serum prostate-specific antigen
test and digital rectal examination [13]. Prostate-specific
antigen is a kallikrein-like serine protease produced in
the epithelial cells of the prostate, which is organ but
not prostate cancer specific [14]. Screening for prostate
cancer using prostate-specific antigen levels aims to de-
tect prostate cancer early stage for better management
of prostate cancer and reduction of disease specific mor-
tality [15]. Elevated prostate-specific antigen levels indi-
cate greater likelihood of prostate cancer but can also
attributable to other health conditions such as prosta-
titis, benign hyperplasia prostatic inflammation [11, 14].
The sensitivity of a prostate-specific antigen levels above
4.0 ng/mL for detecting prostate cancer ranges from 63
to 83% hence serves as a reference point for further
prostate cancer analysis [16, 17]. However, the risk of
prostate cancer has been reported in relation to low
prostate-specific antigen values range from 6.6 to 26.9%
from prostate-specific antigen levels of < 0.5 ng/mL and
3.1 ng/mL - 4 ng/mL respectively [16]. Hence, many
men may still have likelihood of prostate cancer develop-
ment despite having low serum prostate-specific antigen
[18]. More so, it has been speculated that men with the
higher prostate specific antigen levels are more likely to
harbour premalignant lesion also known as small pros-
tate cancer that progresses to become clinically apparent
decades later [19]. Some studies have shown that there
is risk of prostate cancer development despite the low
prostate specific antigen levels over years [19, 20]. Pros-
tate cancer symptoms include frequent urination, noc-
turia, difficulty in starting and maintaining a steady
stream of urine, haematuria, and dysuria [21]. Some of
the symptoms such as haematuria, dysuria and nocturia
are synonymous with those of schistosomiasis infection.
Therefore, men that reside in schistosomiasis endemic
areas may confuse prostate cancer symptoms with those
of schistosomiasis.
Schistosomiasis is a disease caused by the trematodes
of different species of the genus Schistosoma [22]. The
disease causes irreversible damages to certain body or-
gans such as the bladder and the liver and accounts for
the high burden of morbidity in areas where it is en-
demic [23]. More than 700 million people are at risk of
contracting schistosome infection, with 200 million of
them residing in sub-Saharan Africa [24–26] .An esti-
mated 95.2 million adults are at risk of schistosomiasis
infection [23]. Schistosoma haematobium and Schisto-
soma mansoni are the two species endemic in
Zimbabwe. Although S. haematobium is relatively less
important as a cause of mortality compared to S. man-
soni, its effects can trigger other diseases such as cancer
and its combination with other diseases such as HIV
and cancer may result in high mortality [23]. S. haema-
tobium adult worms produce hundreds to thousands of
ova daily [27]. The eggs are passed out through urine
but some of the ova penetrate and lodge in the vessel
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walls of nearby tissues mainly in the bladder, bowel and
to a lesser extent the seminal vesicles, vas deferens, pros-
tate gland, spermatic cord and the penis resulting in
MGS [28, 29]. Whilst, S. mansoni paired adult trema-
todes that reside in the peripheral vessels of the intes-
tines causing intestinal schistosomiasis [22].
Prostatic MGS is uncommon however; past or active
schistosome ova were identified in the prostate and sem-
inal vesicles of approximately 15% of all males between
the ages of 3 months to 70 years in an autopsy study
done by Cohen et. al. in 1993 in Southern Africa [30].
Additionally, in 1970, Gelfand et. al. in Zimbabwe re-
ported of approximately 21% of the cadavers having
schistosome eggs in the prostate [31]. In response to the
embedded schistosome eggs, the body will orchestrate
granuloma lesions formation due to inflammation in the
genitals causing genital lesions [32]. The genital lesions
may lead to events that could indirectly lead to carcino-
genesis. S. haematobium and S. mansoni associated
prostate adenocarcinoma cases has been reported in dif-
ferent schistosomiasis endemic countries such as
Angola, Egypt, South Africa and Brazil and also schisto-
somiasis non endemic areas such as USA and Iraq [33–
36]. Thus available literature, though very limited, sug-
gests a possible association of schistosomiasis infection
with the development of prostate cancer particularly in
schistosomiasis endemic areas.
One of the 10 provinces in Zimbabwe, Mashonaland
East, has the second highest schistosomiasis prevalence
amongst school going aged children ranging from 9.0 to
53.0% across the province [37]. Approximately 13% of
the number of all cancer patients reported in Zimbabwe
in 2015 were from Murehwa District, Mashonaland East
[8]. This is the highest number of registered cancer pa-
tients in any province after the two-referral cities in
Zimbabwe, Harare (35%) and Bulawayo (16%) [8].
Therefore, Murehwa District served as the ideal study
area to assess the association of the two diseases. Men
that reside in schistosome endemic areas have constant
exposure to schistosome infections and may have active
or history of MGS infections that could indirectly lead
to prostate carcinogenesis. We therefore, conducted this
study to determine the prevalence of schistosomiasis and
association between schistosomiasis and risk of prostate
cancer development in residents of a schistosomiasis en-
demic area.
Methods and materials
Study design and study area
A cross sectional study was conducted in Murehwa Dis-
trict in 2019, targeting adult males from different villages
(Kapasura, Magaya, Guzha, Dombwe, Mutize, Kareza,
Inyagui and Jekwa). Murehwa is located in the Mashona-
land East Province and its geographical coordinates are
17°38′35.59“ S 31°47’2.40” (Fig. 1). The overall popula-
tion of Murehwa District is 199,607 and 47% are males
[38]. The District consists of more than 90% of the area
is rural areas. It is wet season is warm and mostly cloudy
and the dry season is comfortable and mostly clear.
There is poor sanitation and some of the residents prac-
tise open defecation.
Sample size calculation and sampling
A sample size of 245 including 20% add on to account
for drop out was calculated based on the inferred schis-
tosomiasis prevalence for adults of 15.8% (a third of the
47.4% for the school aged children) [37]. We purposely
recruited male adults aged 18 years and above residing
Murehwa District, Zimbabwe. However, the number of
participants recruited ended up being 366 because more
men who met the study criteria. The study inclusion cri-
teria were as follows: i) 18 years and above, ii) having
lived in the study area all their life iii) with or without
schistosomiasis iv) with or without prostate cancer and
v) gave consent to be in the study during baseline. The
exclusion criteria were as follows: i) aged of less than 18
years and below, ii) did not give consent to be in the
study.
Parasitological diagnosis
Urine samples of approximately 50 mL were collected
from each study participant on three consecutive days
between 10:00 h and 14:00 h, a period when there is peak
number of eggs in the urine. The urine samples were
processed and examined using the urine filtration tech-
nique [39]. The number of eggs were expressed per 10
mL of urine. Each urine sample was tested for haema-
turia by dipping the urinalysis reagent strip ends (Spin-
react, SA lot URS 7100133A) into urine for at least 1
min. The test area for micro-haematuria was compared
with a standard chart as per manufacturer’s instructions.
The strength of the colour change indicates varying con-
centrations of blood present in the sample ranging from
negative, trace (±), light (+), moderate (++) and heavy
(+++).
Stool samples also collected over 3 days, processed,
and examined using the Kato–Katz method [40]. The S.
mansoni eggs were expressed per gram of stool. Partici-
pants were diagnosed positive for schistosomiasis infec-
tion if any of the two species of the parasite egg was
detected in their urine or stool samples. Infection inten-
sity was classified in accordance with the World Health
Organization (WHO) guidelines as follows: for S. hae-
matobium, no infections 0 eggs/10 mL, light infection
≤10 eggs/10 mL and heavy infection ≥50 eggs/10 mL and
for S. mansoni, light infections < 100 eggs per gram
(epg), moderate infections ≥100 < 400 epg and heavy in-
fections ≥400 epg [41]. Participants who tested positive
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for schistosomiasis by egg count for any of the species
were treated with praziquantel (PZQ) at the standard
dose of 40 mg/kg per body weight.
History of schistosomiasis infection characterisation
A structured questionnaire designed to extract the fol-
lowing information was administered to all study partici-
pants: past/history of schistosome infection, treatment of
previous schistosomiasis infection, currently suspecting
if they have schistosomiasis infection, blood in urine,
pain during urination, felt pain in their genital area and
if they have been screened for prostate cancer before.
Determination of prostate specific antigen
Serum was obtained from the venous blood into blood
collecting tubes without anti-coagulant (BD vacutainers
Lot- 7,114,655). Qualitative detection of prostate-specific
antigen levels was done using enzyme linked immuno-
sorbent assay (ELISA) using the R &D Human Kallikrein
3/prostate-specific antigen Duo Set ELISA; DY1344 and
R&D systems catalog # DY008 ancillary kit (96 well mi-
croplates, plate sealers, substrate solution, stop solution,
plate coating buffer (PBS), wash buffer, and reagent
diluent concentrate) according to the manufacturer’s in-
struction. All samples and standards were measured in
duplicate and concentrations were determined from a
standard curve using mean optical density values. Serum
prostate-specific antigen concentrations were expressed
as ng/mL.
Statistical methods
Data was analysed using graph pad prism version 6.0
and Statistical Package for Social Sciences (SPSS) statis-
tics version 16. Descriptive statistics were applied on the
following variables; age, infection status and infection in-
tensity. Mann Whitney test was used to determine the
differences of prostate-specific antigen infection statuses:
schistosomiasis positive and negative, haematuria posi-
tive and haematuria negative and those with a history of
schistosomiasis and those without. Kruskall Wallis test
was used to determine differences of schistosomiasis in-
fection intensities. Multivariable logistic regression was
used to estimate the association of schistosomiasis infec-
tion status, history of schistosomiasis and haematuria in-
tensity with schistosomiasis infection status. Spearman’s
rank correlation (Spearman’s rho) was used to determine
Fig. 1 Map of Murehwa District, Mashonaland East Province, Zimbabwe and study focal meeting points
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association between schistosomiasis infections and pros-
tate cancer development and schistosomiasis infections
and hemoglobin levels. Multiple regression model using
schistosomiasis infection status, history of schistosomia-
sis and haematuria intensity was used to predict
prostate-specific antigen levels > 0 ng/mL (indicator for
risk of prostate cancer development). P values < 0.05
were considered significant. The mean and the standard
deviation were used in reporting data values.
Results
In total, 366 individuals aged 18 to 95 years participated
in the study. Twelve percent (12.3%) were infected with
S. haematobium and 1.4% had S. mansoni, giving an
overall schistosomiasis infection prevalence of 13.7%. Of
the 45 men infected with S. haematobium, 19 (42%) had
light infections and 26 (58%) had heavy infections. For
those infected with S. mansoni, 1 participant with 120
epg (20%) had moderate infection intensity and 4 (80%)
had light infections with 20 ± 12 epg. Kapasura commu-
nity had the highest schistosomiasis infection (37.74%)
followed by Kareza (13.51%), Magaya (13.18%), Inyagui
(11.9%), Guzha (10%), Jekwa (3.45%) and Dombwe
(3.22%). No schistosome infections were detected in par-
ticipants from Mutize village. Characteristics of the par-
ticipants by villages are shown in Table 1. Table 2 shows
that infection intensity was significantly higher in the <
50 years age group (0.1902 ± 0.4580 log10 mean eggs/10
mL + 1) compared to the > 50 years age group
(0.07755 ± 0.3182 log10 mean eggs/10 mL + 1; p < 0.05).
Of the 50 positive for schistosomiasis infection, 18 were
haematuria positive and 31 were negative. Seventeen of
the 316 participants who tested negative for schistosom-
iasis infection were positive for haematuria. Haematuria
intensity among the 35 participants were as follows: 3
(8.6%) showed 5–10 mark, 6 (17.1%) showed trace ±, 2
(5.7%) showed +, 7 (20%) showed ++ and 17 (48.6%)
showed +++. Logistic regression was used to predict the
likelihood of the participants to have schistosomiasis in-
fection. The predictor values were history of
schistosomiasis infection, haematuria status, villages and
age. The model was statistically significant X2 (10, n =
325) = 71.420 p < 0.001. The model explained 36.4%
(Nagelkerke R [2]) of the variance in schistosomiasis in-
fection and correctly classified 89.5% of the cases.
Haematuria status p < 0.001, age p = 0.017 and all villages
p = 0.004 contributed significantly to the model, but his-
tory of schistosomiasis infection (p = 0.268) and villages
(p > 0.05) did not contribute significantly to the model
(Table 3). Participants in Kapasura village (OR 3.220;
95% C.I. 0.918–11.3, p > 0.05) were more likely to have
schistosomiasis infection than the other villages
(Magaya, Kareza, Inyagui, Guzha, Jekwa, Dombwe and
Mutize). History of schistosomiasis infection was associ-
ated with having schistosomiasis infection (OR 0.594;
C.I. 0.211–1.67, p > 0.05).
Structured questionnaire analysis
Data from the questionnaire is summarized in Table 4.
Eighty-six of the participants suspected they had schisto-
somiasis infection because they experienced pain during
urination, noticed blood in their urine and were fre-
quently urinating. Two hundred and thirty (68%) of the
participants had schistosome infections during their
younger ages and 33 (13.9%) had current schistosomiasis
infection. Two hundred of the participants had schisto-
somiasis infection between the ages of 1 to 20 years. One
hundred and eighty three participants (77.5%) were at
some point treated for schistosomiasis infection, 36
(15.3%) had never been treated and 17 (7%) could not
recall having been treated for schistosomiasis. Thirty-
five participants (10.6%) were noticing blood in their
urine, 104 (32.6%) felt pain during urination and 88
(27.5%) felt pain in their genital area. Three hundred
and fifteen participants (92.6%) had never been screened
for prostate cancer and of the 10 that had been screened
only 2 have confirmed prostate cancer. Of the 2 prostate
cancer diagnosed participants, one was a 69 year old
man who resided in Inyagui village, with a history of
schistosomias infection during his teenage years which
Table 1 Number of participants and schistosomiasis prevalence in each community
Site Number of participants S. haematobium infected S. mansoni infected Schistosomiasis prevalence
Mutize 23 0 0 0.00%
Dombwe 31 1 0 3.22%
Jekwa 29 1 0 3.45%
Guzha 60 6 0 10.0%
Inyagui 42 4 1 11.9%
Magaya 91 11 1 13.18%
Kareza 37 3 2 13.51%
Kapasura 53 19 1 37.74%
Total 366 45 5 13.66%
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he was treated for using traditional methods. He had no
active schistosome infection and he suspected he had
schistosomiasis infection because he felt pain during
urination however he neither had active schistosome in-
fection nor haematuria. The second participant from
Mutize village in his 60s diagnosed with prostate cancer
had history of schistosomiasis infection during his teen-
age years and he was not treated for the infection. He
did not have active schistosomiasis infection.
Prostate specific antigen levels analysis
Of the three hundred and sixty six participants, 198 (166
schistosomiasis negative and 32 schistosomiasis positive)
had detectable prostate-specific antigen levels > 0 ng/mL
ranged from 0.118 to 8.100 ng/mL with a mean of 0.8425 ±
SD 1.249 ng/mL. Eight participants had prostate-specific
antigen levels > 4 ng/mL and 5 of the 8 participants had his-
tory of schistosome infections during their younger ages.
Spearman’s rank-order correlation showed no correlation
between prostate-specific antigen levels of > 4 ng/mL
(5.324 ± 1.568) and log10 mean egg + 1 (1.057 ± 0.6730; p =
0.333). Prostate-specific antigen levels among the schisto-
somiasis infected group (1.208 ± 1.557 ng/mL) were signifi-
cantly higher than for the schistosomiasis uninfected group
(0.7721 ± 1.173 ng/mL; p = 0.0221) as shown in Fig. 2.
Prostate-specific antigen levels of participants without
haematuria were higher (0.8740 ± 1.308 ng/mL) but not
statistically significant than for those with haematuria
(0.5763 ± 0.478 ng/mL; p > 0.05. Similarly prostate-specific
antigen levels for participants without history of schisto-
somiasis infection (1.184 ± 1.768 ng/mL) were not signifi-
cantly higher than for those with history of schistosomiasis
infection (0.7882 ± 1.090 ng/mL; p > 0.05). Log10 mean egg
counts + 1 of individuals that were positive for schistosom-
iasis and haematuria (1.400 ± 0.5038 eggs/10mL) were sig-
nificantly higher (Fig. 3) than schistosomiasis positive and
but haematuria negative group (0.8859 ± 0.4128 eggs/10
mL; p = 0.0009). However, there was non-significant higher
mean eggs for those with a history of schistosomiasis
(1.130 ± 0.5103 eggs/10mL) compared to those without
history of schistosomiasis (0.9389 ± 0.5205 eggs/10mL; p =
0.1183). Prostate-specific antigen levels in participants with
both S. mansoni and S. haematobium light infection inten-
sity group (n = 15; 0.7721 ± 1.173 ng/mL) was significantly
higher compared to the heavily infected (n = 17; 1.141 ±
1.833 ng/mL) and schistosome uninfected infection status
(p = 0.0341) as shown in Fig. 4. Furthermore, there was
non-significant higher prostate specific-antigen levels
among the S. mansoni (n = 3; 2.275 ± 2.072) infected partic-
ipants compared to S. haematobium (n = 32; 1.0970 ±
1.498) infected (p = 0.1105). Participants older than 50 years
had significantly higher prostate specific-antigen levels
(0.7212 ± 1.313 ng/mL) compared to participants < 50 years
old (0.4159 ± 0.8622 ng/mL; p (0.0140) < 0.05 (Fig. 5).
Table 2 Prevalence and intensity of schistosomiasis by age group
Age group n (%) Schistosomiasis infected
n (%)
Mean schistosome egg count
(log10 ± SD)
p Value
(Mann-Whitney)
< 50 years 216 (59.0) 40 (10.9) 0.1902 ± 0.4580 0.002
> 50 years 146 (39.9) 9 (2.5) 0.07755 ± 0.3182
Missing ages 4 (1.1) 0 0
Total 366 (100) 49 (13.4)
Table 3 Multivariable logistic regression predicting decision from history of schistosomiasis infection, haematuria status, villages and
age
Coefficient Wald X2 P Odds Ratio (95.0% C.I.)
Haematuria Status −2.723 30.153 0.001 0.066 (0.025–0.174)
History of schistosomiasis infection −.574 1.225 0.268 0.563 (0.204–1.556)
Villages 20.762 0.004
Dombwe −1.475 1.455 0.228 0.229 (0.021–2.515)
Jekwa − 1.875 2.334 0.127 0.153 (0.014–1.7)
Mutize −18.262 .000 0.998 0.000 (0.00)
Kapasura 1.169 3.333 0.068 3.220 (0.918–11.298)
Kareza −.657 .550 0.458 0.519 (0.091–2.942)
Magaya −.346 .270 0.604 0.708 (0.192–2.611)
Guzha −1.147 2.106 0.147 0.318 (0.067–1.495)
Age −.029 5.651 0.017 0.972 (0.949–0.995)
Constant 1.960 5.121 0.024
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Multiple regression analysis was run to predict
prostate-specific antigen levels > 0 ng/mL as an indicator
for risk of prostate cancer development from schisto-
somiasis infection status, history of schistosomiasis in-
fection and haematuria intensity predicted prostate-
specific antigen levels > 0 ng/mL F (3, 184) = 3.872, P
(0.010) < 0.05, R2 = 0.059. Two variables, schistosomiasis
infection status p (0.07) < 0.05 and haematuria intensity
p = (0.026) < 0.05) contributed significantly to the predic-
tion model. The highest contributing predictor was the
schistosomiasis infection status (β = 216) followed by
haematuria intensity (β = − 177) to explain prostate-
specific antigen levels. History of schistosomiasis infec-
tion was not a significant predictor to the model (p
(0.056) > 0.05) and hence did not contribute in explain-
ing prostate-specific antigen levels > 0 ng/mL, when the
other two significant predictors are in the model.
Of the 45 participants with S. haematobium infection
29 had detectable mean log10 (egg count+ 1); prostate-
specific antigen levels of 0.2584 ± 0.2128 ng/mL and
log10 (mean egg count + 1); 1.121 ± 0.5371 eggs/10 mL.
A Spearman’s rank-order correlation showed an inverse
correlation between prostate-specific antigen levels and
infection intensity of participants that had schistosomia-
sis infection (p < 0.05; Fig. 6). Similarly as shown in Fig. 7,
there was a negative correlation between log10 (egg
count + 1) prostate-specific antigen levels log10
(0.2246 ± 0.1858 ng/mL) and S. haematobium mean egg
counts (1.169 ± 0.5568 eggs/10 mL) among 24 partici-
pants with a history and active schistosome infections
(p < 0.05).
Discussion
Schistosomiasis induced prostatic cancer is not yet well
characterised in populations living in schistosomiasis en-
demic countries to at least establish the association of
male genital schistosomiasis with prostate cancer devel-
opment. The main aim of this study was to determine
the association of schistosomiasis infections on prostate
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Fig. 3 Infection intensity according to haematuria and history of
schistosomiasis. HoShI - history of schistosomiasis infection, Hae -
haematuria, −ve - negative, +ve - positive
Fig. 4 Prostate-specific antigen levels differences and
schistosomiasis infection intensity
Table 4 Structured Questionnaire Responses
Parameter Yes
% (n)
No
% (n)
History of schistosomiasis infection 68 (230) 32 (108)
Treated for schistosomiasis infection 77.5 (183) 15.3 (36)
Currently suspected of schistosomiasis infection 25.8 (86) 74.2 (247)
Noticed blood in their urine 10.6 (35) 89.4 (294)
Felt pain during urination 32.6 (104) 67.4 (215)
Feel pain in the genital area 27.5 (88) 72.2 (231)
Screened for prostate cancer 3.1 (10) 92.6 (315)
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cancer development among individuals residing in schis-
tosomiasis endemic rural community. We found an as-
sociation between prostate-specific antigen levels and
schistosomiasis infection status among the study popula-
tion. Additionally, we found some significant association
between prostate-specific antigen levels of individuals
with schistosomiasis infection having history of schisto-
somiasis infection with schistosomiasis infection inten-
sity. In contrast to Elfaki et. al. in 2015, they did not find
detectable prostate-specific antigen levels in serum sam-
ples from individuals that had schistosomiasis infection
[21] and concluded that there was no association be-
tween schistosomiasis and prostate cancer. Even though
we detected prostate-specific antigen levels in individuals
with schistosomiasis, we cannot infer an association of
the disease with prostate cancer development because
prostate-specific antigen levels serve as reference points
for further prostate cancer analysis and not definite
prostate cancer hence further examinations such as
biopsy is required. Moreover, there was no association
between prostate-specific antigen levels greater than 4
ng/mL and schistosomiasis infection intensity. There-
fore, we could not conclusively establish the association
of schistosomiasis infection and a greater likelihood risk
of prostate cancer development probably due to only 3
participants with schistosomiasis and prostate-specific
antigen levels > 4 ng/mL. Interestingly, a study done by
Catalona et. al. revealed prostate malignancy in 33% of
112 men with a prostate specific antigen levels ≥4 μg/L
showing low specificity of prostate specific antigen ele-
vated levels on prostate cancer diagnosis [42].
The elevated prostate-specific antigen levels we ob-
served could have be attributed to old age, prostatitis, be-
nign hyperplasia, urinary tract infections, ejaculation,
prostate injury and medicine prolonged bicycles rides [43].
Prostatic inflammation due to S. haematobium or S. man-
soni ova deposits can lead to elevated levels of systemic
prostate-specific antigen levels [5, 44, 45]. Furthermore,
other studies that reported prostatic schistosomiasis cases
with high prostate-specific antigen levels were not associ-
ated with prostatic schistosomiasis cancer [44, 45]. Other
studies have reported mixed outcomes whereby, men with
prostate-specific antigen levels below 4.0 ng/mL had pros-
tate cancer and on the other hand, men with higher levels
of prostate-specific antigen did not have prostate cancer
[18]. The presence of prostatic inflammation may disrupt
the prostatic environment with time and may result in ele-
vated prostate specific antigen levels and a greater risk of
prostate cancer development [19]. Additionally, inflamma-
tion has been implicated to result to oxidative stress that
could be a risk for prostate cancer development [46]. In
view of this and the evidence we provided on association
between history schistosome infections with active
Fig. 6 Prostate-specific antigen levels relationship with
schistosomiasis infection intensity
Fig. 7 Prostate-specific antigen levels relationship with
schistosomiasis infection intensity of those with a history
of schistosomiasis
Fig. 5 Prostate-specific antigen levels differences by age groups
(> 50 and < 50)
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schistosome infections and risk of prostate cancer we rec-
ommend that in schistosomiasis endemic areas men with
both elevated and low prostate-specific antigen levels
should undergo further tests for prostate cancer.
The higher prostate-specific antigen levels detected
among the schistosomiasis positive group compared to the
schistosomiasis negative group could be due to schistosom-
iasis infection and not necessarily an indication of prostate
cancer development; that could also be due to prostatic in-
flammation due to MGS [47]. However, prostate-specific
antigen levels may not be due to schistosome infections but
other conditions mentioned above. This could be because
of higher prostate-specific antigen levels detected in the
schistosomiasis negative group compared to the schisto-
somiasis severe intensity group. The higher the prostate-
specific antigen level value, the higher the likelihood risk of
prostate cancer [11] and the lower the prostate-specific
antigen value the less likely the risk of prostate cancer. Risk
of prostate cancer has been reported in relation to low
prostate-specific antigen values range of 6.6 -26.9% from
prostate-specific antigen levels < 0.5 ng/mL and 3.1 ng/mL -
4 ng/mL respectively [11]. Also men with low prostate spe-
cific antigen levels were reported to reflect higher risk of
prostate cancer development [19, 20]. This suggests that
majority of the participants in the study area with low pros-
tate specific antigen levels might have a likelihood to de-
velop prostate cancer and hence they may need further
prostate cancer assessments.
On the contrary to observations of prostatic schistosom-
iasis infection progressing over time as represented by a pa-
tient with prostate adenocarcinoma and high prostate-
specific antigen levels (11.59 ng/mL) reported by Metrogos
et. al in 2017 [36], we observed insignificant lower prostate-
specific antigen levels of among participants with history of
schistosomiasis infection compared to those without history
of schistosomiasis infection. Therefore, history of schisto-
somiasis infection may not necessarily an indicator of pros-
tate cancer development. Moreover, Sharma et. al. in 2015
reported of a patient with benign prostatic hyperplasia with
S. haematobium prostatic infestation and low prostate-
specific antigen levels [48] indicating that prostatic MGS
might not result to prostate cancer over time. However,
men with history of schistosome infections could be con-
tinuously suffering or will suffer from complications of the
disease such as cancer development in the future.
Prostate cancer has been diagnosed in very few men who
are younger than 50 years compared to men aged > 50 [49].
Despite lower prostate-specific antigen levels in participants
with < 50 years old compared to men > 50 years, men with
prostate-specific antigen > 1 ng/mL at 40 years were re-
ported to be at increased risk of being diagnosed with ad-
vanced or metastatic prostate cancer [50]. Moreover,
unusual 3 cases of young males below the age of 30 were
reported to have schistosomiasis prostatic adenocarcinoma
[30]. It is therefore possible that men with history of schis-
tosome infections and residing in schistosomiasis endemic
area could be asymptomatically suffering from schistosome
complications and may have a higher risk of having pros-
tate cancer regardless of their age.
Current data on S. haematobium and S. mansoni
epidemiology in Zimbabwe is from school-aged chil-
dren [37]. We found that the overall prevalence of
schistosomiasis was 13.7% in adult male individuals in
the study area. Haematuria status, age and villages
were significant predictors of schistosomiasis infection
status. This showed that schistosomiasis is prevalent
not just in children who are the main targets for
mass drug administration, but also in the adult males.
Although haematuria is known to be a predictor of
schistosomiasis infection [51], in adults it might ac-
count for other infections such as sexually transmit-
ted diseases. Kapasura village residents were 3.2 times
more likely to have schistosomiasis infection com-
pared to the other villages probably because of their
involvement in activities such as cattle herding, fish-
ing and gardening that constantly get them in contact
with cercariae infected water sources at nearby river.
Distressingly, approximately 3% of the participants
have had the opportunity to be screened for prostate
cancer hence there is a need for regular prostate can-
cer screening in the study area. Lack of resources and
limited health centres with prostate cancer testing fa-
cilities in the area means many men are not aware of
their prostate cancer status. Concurrent existence of
prostate cancer and Schistosoma ova have been re-
ported in very limited cases reports, however, the re-
lationship of the two diseases still remains poorly
understood.
Conclusion
The association of schistosomiasis and risk of prostate can-
cer amongst adult males shows to be more prominent in
schistosome endemic area of Murehwa District. However,
since existing measurement can only detect inflammation
due to egg invasion more is required to further characterize
schistosomiasis prostatic carcinoma development. We
found an association between urogenital schistosome infec-
tions, history of schistosomiasis infection and prostate-
specific antigen levels, while prostate-specific antigen levels
> 4 ng/mL were not associated with current schistosome in-
fections. We conclude that S. haematobium egg burden in
adult males was associated with the risk of prostate cancer
development residing in Murehwa District, Zimbabwe.
Limitations
We did not have bigger sample size to fully represent the
study area would include both S. haematobium and S.
mansoni infections and confirmed prostate cancer
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diagnosed cases to provide more evidence on the differ-
ences on the association of one of the two schistosome
species with prostate cancer development. Prostate biopsy
was not done to confirm and determine the magnitude of
prostatic schistosomiasis and prostate cancer diagnosis
hence, we could only determine risk of prostate cancer.
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